ClinicalTrials.gg
CompletedNCT02937818Updated Jun 7, 2024Results posted

A Phase II, Study to Determine the Preliminary Efficacy of Novel Combinations of Treatment in Patients With Platinum Refractory Extensive-Stage Small-Cell Lung Cancer

A Phase 2 interventional study of Durvalumab and Tremelimumab and AZD1775 and carboplatin (CBPT) in Platinum Refractory Extensive-Stage Small Cell Lung Carcinoma, sponsored by AstraZeneca. Completed at 12 sites in 5 countries. Open to participants aged 18 Years to 130 Years. Per ClinicalTrials.gov, last updated 2024-06-07.

Sponsored by AstraZeneca · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
72
Allocation
Non-randomized
Ages
18 Years to 130 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 36 studies testing carboplatin in Small Cell Lung Carcinoma — 6 open to participants now, 9 under way, 1 of them phase 3. Carboplatin · Small Cell Lung Carcinoma.

Enrollment
9th of 36
72 · median 48
Started
2016
the only one that year
Phase 2
22 of 36
4 open now
Registered
16th of 36
by date
Lead sponsor
1 of 36
AstraZeneca

Among the 36 studies testing carboplatin in Small Cell Lung Carcinoma, this one is the 9th largest by enrollment, is the only one that started in 2016, is one of 22 in phase 2, and was the 16th registered.

Small Cell Lung Carcinoma

1,301 studies on the registry are indexed under Small Cell Lung Carcinoma; 365 are open to participants now.

Browse Small Cell Lung Carcinoma studies →

Open to participants now

6 of the 36 studies testing carboplatin in Small Cell Lung Carcinoma are open now, in 12 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About carboplatin

Carboplatin: first FDA approval 1989 (PARAPLATIN). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 265 Small Cell Lung Carcinoma studies recruiting now, 175 (66%) set no upper age limit and 66 (25%) stop at 75 or younger; 3 take children under 18; 8 take healthy volunteers.

This study: 18 Years to 130 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 36 studies testing carboplatin in Small Cell Lung Carcinoma, or all of them as a file.
02

Study summary

Study design This is a Phase II, open-label, multi-drug, multi-center, multi-arm, signal-searching study in patients with extensive-stage small-cell lung cancer (SCLC) who have refractory or resistant disease from prior platinum-based chemotherapy.

Read the detailed description

This study is modular in design, allowing evaluation of the preliminary efficacy, safety, tolerability, and immunogenicity of novel combinations of immunotherapies and/or deoxyribonucleic acid (DNA) damage repair inhibitors in patients with platinum refractory or resistant extensive-stage-disease SCLC. Patients who have progressive disease (PD) during first-line platinum-based chemotherapy (platinum refractory) or PD within 90 days after completing first-line platinum-based chemotherapy (platinum resistant) will be enrolled to the study. The primary objective of the study is to assess the preliminary efficacy of each treatment arm based on objective response rate (ORR).

This study consists of a number of arms (sub-studies), each evaluating the efficacy, safety, and tolerability of a specific agent or combination. This study was initially open with 2 arms (Arms A and B), and additional arms may open, provided there is compelling rationale for the combination and safe and tolerable doses and schedules have been determined from ongoing Phase I studies. There are 2 pre-defined arms:

A. Durvalumab + tremelimumab followed by durvalumab monotherapy B. AZD1775 + carboplatin (CBDP)

Further arm was added in amendment 3:

C. AZD6738 + olaparib Amendment #4 was updated with possibility to allow expansion of any arm, to a total of 40 eligible subjects, based on Review Committee assessment of data from the first 20 subjects (from Stage 1 and Stage 2). Currently Arm A will enroll 20 additional patients into expansion.

03

Conditions studied

  • Platinum Refractory Extensive-Stage Small Cell Lung Carcinoma

Keywords

  • Platinum Refractory Extensive-Stage Carcinoma, Small Cell Lung
  • Platinum Refractory Extensive-Stage Oat Cell Carcinoma of Lung
  • Platinum Refractory Extensive-Stage Oat Cell Lung Cancer
  • Platinum Refractory Extensive-Stage Small Cell Cancer Of The Lung
  • Platinum Refractory Extensive-Stage Small Cell Lung Cancer
04

Who can participate

Ages eligible
18 Years to 130 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion criteria (applicable to all arms)

  • Adults with or cytologically documented ED SCLC who have demonstrated progressive disease either during platinum-based chemotherapy (platinum ) or within 90 days of completing platinum based-chemotherapy (platinum resistant) and have not received further treatment.
  • must be asymptomatic or treated and stable off and anti-convulsants for at least 1 month prior to study treatment.
  • At least 1 lesion, not previously irradiated, that can be accurately measured at baseline (per v 1.1 guidelines)
  • of at least 8 weeks.
  • WHO/ PS of 0-1 at enrollment.

Inclusion criteria (Arm A specific)

  • Body weight >30 kg.
  • No prior exposure to immune mediated therapy, excluding therapeutic anticancer vaccines.

Inclusion criteria (Arm B specific) • Able and willing to swallow oral medication.

Inclusion criteria (Arm C specific)

  • Able and willing to swallow oral medication.

Exclusion criteria (applicable to all arms):

  • Participation in another clinical study, major surgery, radiation therapy within 28 days.
  • Any condition that, in the opinion of the Investigator, would interfere with the evaluation of the IP or interpretation of patient safety or study results.
  • Uncontrolled intercurrent illness, including but not limited to interstitial lung disease.
  • History of another primary , or spinal cord compression.

Exclusion criteria (Arm A specific)

  • Active disease, including a paraneoplastic syndrome.
  • Active or prior documented autoimmune or inflammatory disorders.
  • Any unresolved toxicity ( Grade >2) from previous anticancer therapy.
  • Active infection including tuberculosis, , or C.

Exclusion criteria (Arm B specific)

  • Prior exposure to any WEE1 inhibitors.
  • Products known to be sensitive to substrates or CYP3A4 substrates with a narrow therapeutic index, or to be moderate to strong inhibitors/inducers of CYP3A4. Co-administration of rosuvastatin, atorvastatin, simvastatin and lovastatin, aprepitant or fosaprepitant or any herbal preparations. Grapefruit and Seville oranges should be avoided while taking AZD1775.
  • Any known or to IP or CBDP.
  • > 470 msec or congenital long QT syndrome.
  • Any current or within 6 months cardiac diseases ≥ Class 2: unstable angina pectoris, congestive heart failure, acute MI, conduction abnormality not controlled with pacemaker or medication, significant ventricular or supraventricular arrhythmias.
  • A recent history of Torsades de pointes.

Exclusion criteria (Arm C specific)

  • Cytotoxic chemotherapy within 21 days of Cycle 1 Day 1 is not permitted
  • Previous treatment with a PARP inhibitor (including olaparib) or ATR inhibitor
  • Concomitant use of known strong CYP3A inhibitors and moderate CYP3A inhibitors
  • Concomitant use of known strong and moderate CYP3A inducers
  • Persisting (> 4 weeks) severe pancytopenia due to previous therapy
  • Cardiac dysfunction
  • Refractory nausea and vomitting, chronic gastrointenstinal diseases or previous significant bowel resection
  • Patients with uncontrolled seizures
  • Intenstinal obstruction or CTCAE grade 3 or grade 4 GI bleeding within 4 weeks before dosing
Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
72 participants (actual)

Study arms

  • Experimental
    ARM A

    Drug: Durvalumab and Tremelimumab

  • Experimental
    ARM B

    Drug: AZD1775 and carboplatin (CBPT)

  • Experimental
    ARM C

    Drug: AZD6738 and olaparib

Interventions

  • DrugDurvalumab and Tremelimumab

    Durvalumab + tremelimumab via intravenous (IV) infusion every 4 weeks (q4w), starting on Week 0, for up to a total of 4 months (4 cycles) followed by durvalumab monotherapy via IV infusion q4w, starting on Week 16 until PD, or for other discontinuation criteria.

  • DrugAZD1775 and carboplatin (CBPT)

    Drug pages: Adavosertib · Carboplatin

    AZD1775 twice daily (oral) for 2.5 days from Day 1 + CBDP area under the curve 5 (Day1) (IV); every 3 weeks.

  • DrugAZD6738 and olaparib

    Drug pages: Ceralasertib · Olaparib

    AZD6738 once a day (oral) for 7 days from Day 1 + olaparib twice a day(oral) for 28 days from Day 1, every 4 weeks

This study also gives Durvalumab, Tremelimumab. No intervention listed here names it: that was found by reading the record.

06

What researchers measure

Primary outcomes

  1. Number of Participants With Overall Response

    Overall Response Rate (ORR) using Investigator assessments according to Response Evaluation Criteria In Solid Tumors (RECIST) 1.1. ORR was defined as the number (percentage) of participants with a confirmed Complete Response (CR) or confirmed Partial Response (PR) and was estimated for each treatment arm with corresponding 2-sided 95% exact confidence intervals (CIs). A confirmed response of CR/PR meant that a response of CR/PR was recorded at one visit and confirmed by repeat imaging, preferably at the next regularly scheduled imaging visit, and not less than 4 weeks after the visit when the response was first observed, with no evidence of progression between the initial and CR/PR confirmation visit.

    Time frame: Until disease progression [PD] (Up to 3.5 Years)

Secondary outcomes

  1. Duration of Response (DoR)

    The DoR was defined as the time from the date of first documented response (which was subsequently confirmed) CR/PR until the date of documented progression, or death in the absence of disease progression. The DoR in participants with confirmed objective response are reported.

    Time frame: Until disease progression or data cut-off or Death (Up to 3.5 Years)

  2. Percentage of Participants With Disease Control at 12 Weeks

    The disease control rate (DCR) at 12 weeks was defined as the percentage of participants who had a best objective response of CR or PR in the first 13 weeks or who had demonstrated stable disease (SD) for a minimum interval of 11 weeks following the start of study treatment. The DCR was determined programmatically based on RECIST 1.1 using site Investigator data and all data up until the first progression event.

    Time frame: At 12 Weeks

  3. Time to Response (TTR)

    The TTR (per RECIST 1.1 as assessed by the Investigator) was defined as the time from the date of first dose until the first date of documented response.

    Time frame: Until disease progression or data cut-off or Death (Up to 3.5 Years)

  4. Progression Free Survival (PFS)

    The PFS (per RECIST 1.1 according to the Investigator's assessment) was defined as the time from the date of the first dose of study treatment until the date of objective disease progression or death (by any cause in the absence of progression) regardless of whether the participant withdrew from allocated therapy or received another anti-cancer therapy prior to progression.

    Time frame: Until disease progression or data cut-off or Death (Up to 3.5 Years)

  5. Overall Survival (OS)

    The OS was defined as the time from the date of the first dose of study treatment until death due to any cause.

    Time frame: Until disease progression or data cut-off or Death (Up to 3.5 Years)

  6. Time to Maximum Concentration (Tmax)

    Time to maximum concentration for ceralasertib and olaparib are reported.

    Time frame: Cycle 1 (each cycle was 28 days in length) Day 1 (post-dose)

  7. Maximum Concentration (Cmax)

    Maximum concentration for ceralasertib and olaparib are reported.

    Time frame: Cycle 1 (each cycle was 28 days in length) Day 1 (post-dose)

  8. Partial Area Under the Concentration-time Curve (AUC0-6)

    Partial area under the concentration-time curve for ceralasertib and olaparib are reported.

    Time frame: Cycle 1 (each cycle was 28 days in length) Day 1 (post-dose) and Cycle 1 Day 7 (pre-dose and post-dose)

  9. Area Under the Concentration-time Curve From Time Zero to the Last Measurable Concentration (AUC0-t)

    Area under the concentration-time curve from time zero to the last measurable concentration for Ceralasertib and Olaparib are reported.

    Time frame: Cycle 1 (each cycle was 28 days in length) Day 1 (post-dose) and Cycle 1 Day 7 (pre-dose and post-dose)

  10. Time to Maximum Concentration at Steady State (Tmax,ss)

    Time to maximum concentration at steady state for Ceralasertib and Olaparib are reported.

    Time frame: Cycle 1 (each cycle was 28 days in length) Day 7 (pre-dose and post-dose)

  11. Maximum Concentration at Steady State (Cmax,ss)

    Maximum concentration at steady state for Ceralasertib and Olaparib are reported.

    Time frame: Cycle 1 (each cycle was 28 days in length) Day 7 (pre-dose and post-dose)

  12. Minimum Concentration at Steady State (Cmin,ss)

    Minimum concentration at steady state for Ceralasertib and Olaparib are reported.

    Time frame: Cycle 1 (each cycle was 28 days in length) Day 7 (pre-dose and post-dose)

  13. Area Under the Concentration-time Curve at Steady State (AUCss)

    Area under the concentration-time curve at steady state at steady state for Ceralasertib and Olaparib are reported.

    Time frame: Cycle 1 (each cycle was 28 days in length) Day 7 (pre-dose and post-dose)

  14. Apparent Clearance of Drug at Steady State at Steady State (CLss/F)

    Area under the concentration-time curve at steady state at steady state for Ceralasertib and Olaparib are reported.

    Time frame: Cycle 1 (each cycle was 28 days in length) Day 7 (pre-dose and post-dose)

  15. Serum Concentrations of Durvalumab and Tremelimumab

    Serum concentrations of Durvalumab and Tremelimumab are reported.

    Time frame: Durvalumab: Cycle 1 (each cycle was 4 weeks) Day 1(post-dose); Cycle 2 Day 1(pre-dose); Cycle 5 Day 1 (pre-dose); Tremelimumab: Cycle 1 (each cycle was 4 weeks) Day 1 (post-dose); Cycle 2 Day 1 (pre-dose); Cycle 5 Day 1 (No dose); Cycle 7 Day 1 (No dose)

  16. Plasma Concentrations of Adavosertib and Carboplatin

    Plasma concentrations of Adavosertib and Carboplatin are reported.

    Time frame: Adavosertib: Cycle 1 (each cycle was 21 days) Day 3 (pre-dose and post-dose); Cycle 3 Day 3 (pre-dose and post-dose); Carboplatin: Cycle 1 (each cycle was 21 days) Day 1 (post-dose)

  17. Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)

    An AE is the development of an undesirable medical condition or the deterioration of a pre-existing medical condition following or during exposure to a pharmaceutical product, whether or not considered causally related to the product. SAE is an AE that results in any untoward medical occurrence that results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability, or is a significant medical event.

    Time frame: Day 1 until disease progression, and follow-up visit (Up to 3.5 Years)

07

Results

Posted Sep 9, 2021

Participant flow

The study was conducted between 28-Nov-2016 and 22-Jun-2020, at 11 study centers in 5 countries (Germany, Hungary, Poland, Spain, and Ukraine).

Participant flow — Overall Study
MilestoneArm A: Durvalumab + Tremelimumab (Original Cohort)Arm A: Durvalumab + Tremelimumab (Expansion Cohort)Arm B: Adavosertib + CarboplatinArm C: Ceralasertib (AZD6738) + Olaparib
Started21201021
Completed0000
Not completed21201021
Withdrew: Participants decision2111
Withdrew: Adverse event2411
Withdrew: Disease progression1715719
Withdrew: Condition under investigation worsened0010

Outcome measures

PrimaryNumber of Participants With Overall Response

Overall Response Rate (ORR) using Investigator assessments according to Response Evaluation Criteria In Solid Tumors (RECIST) 1.1. ORR was defined as the number (percentage) of participants with a confirmed Complete Response (CR) or confirmed Partial Response (PR) and was estimated for each treatment arm with corresponding 2-sided 95% exact confidence intervals (CIs). A confirmed response of CR/PR meant that a response of CR/PR was recorded at one visit and confirmed by repeat imaging, preferably at the next regularly scheduled imaging visit, and not less than 4 weeks after the visit when the response was first observed, with no evidence of progression between the initial and CR/PR confirmation visit.

Time frame:
Until disease progression [PD] (Up to 3.5 Years)
Reported as:
Count of participants · Participants
Number of Participants With Overall Response
ParticipantsArm A: Durvalumab + Tremelimumab (Original Cohort)Arm A: Durvalumab + Tremelimumab (Expansion Cohort)Arm B: Adavosertib + CarboplatinArm C: Ceralasertib (AZD6738) + Olaparib
Number of Participants With Overall Response2101
SecondaryDuration of Response (DoR)

The DoR was defined as the time from the date of first documented response (which was subsequently confirmed) CR/PR until the date of documented progression, or death in the absence of disease progression. The DoR in participants with confirmed objective response are reported.

Time frame:
Until disease progression or data cut-off or Death (Up to 3.5 Years)
Reported as:
Median · Months
Duration of Response (DoR)
MonthsArm A: Durvalumab + Tremelimumab (Original Cohort)Arm A: Durvalumab + Tremelimumab (Expansion Cohort)Arm B: Adavosertib + CarboplatinArm C: Ceralasertib (AZD6738) + Olaparib
Duration of Response (DoR)NA (1.5 to NA)3 (3 to 3)—8.5 (8.5 to 8.5)
SecondaryPercentage of Participants With Disease Control at 12 Weeks

The disease control rate (DCR) at 12 weeks was defined as the percentage of participants who had a best objective response of CR or PR in the first 13 weeks or who had demonstrated stable disease (SD) for a minimum interval of 11 weeks following the start of study treatment. The DCR was determined programmatically based on RECIST 1.1 using site Investigator data and all data up until the first progression event.

Time frame:
At 12 Weeks
Reported as:
Number · Percentage of Participants
Percentage of Participants With Disease Control at 12 Weeks
Percentage of ParticipantsArm A: Durvalumab + Tremelimumab (Original Cohort)Arm A: Durvalumab + Tremelimumab (Expansion Cohort)Arm B: Adavosertib + CarboplatinArm C: Ceralasertib (AZD6738) + Olaparib
Percentage of Participants With Disease Control at 12 Weeks38.115.030.038.1
SecondaryTime to Response (TTR)

The TTR (per RECIST 1.1 as assessed by the Investigator) was defined as the time from the date of first dose until the first date of documented response.

Time frame:
Until disease progression or data cut-off or Death (Up to 3.5 Years)
Reported as:
Median · Months
Time to Response (TTR)
MonthsArm A: Durvalumab + Tremelimumab (Original Cohort)Arm A: Durvalumab + Tremelimumab (Expansion Cohort)Arm B: Adavosertib + CarboplatinArm C: Ceralasertib (AZD6738) + Olaparib
Time to Response (TTR)1.8 (1.7 to 1.8)1.8 (1.8 to 1.8)—1.7 (1.7 to 1.7)
SecondaryProgression Free Survival (PFS)

The PFS (per RECIST 1.1 according to the Investigator's assessment) was defined as the time from the date of the first dose of study treatment until the date of objective disease progression or death (by any cause in the absence of progression) regardless of whether the participant withdrew from allocated therapy or received another anti-cancer therapy prior to progression.

Time frame:
Until disease progression or data cut-off or Death (Up to 3.5 Years)
Reported as:
Median · Months
Progression Free Survival (PFS)
MonthsArm A: Durvalumab + Tremelimumab (Original Cohort)Arm A: Durvalumab + Tremelimumab (Expansion Cohort)Arm B: Adavosertib + CarboplatinArm C: Ceralasertib (AZD6738) + Olaparib
Progression Free Survival (PFS)1.91 (1.77 to 4.34)1.77 (1.02 to 2.20)2.60 (0.56 to 4.83)2.92 (1.81 to 4.53)
SecondaryOverall Survival (OS)

The OS was defined as the time from the date of the first dose of study treatment until death due to any cause.

Time frame:
Until disease progression or data cut-off or Death (Up to 3.5 Years)
Reported as:
Median · Months
Overall Survival (OS)
MonthsArm A: Durvalumab + Tremelimumab (Original Cohort)Arm A: Durvalumab + Tremelimumab (Expansion Cohort)Arm B: Adavosertib + CarboplatinArm C: Ceralasertib (AZD6738) + Olaparib
Overall Survival (OS)5.95 (1.91 to 10.61)3.37 (1.91 to 7.66)4.67 (0.56 to 5.98)7.56 (4.21 to 12.58)
SecondaryTime to Maximum Concentration (Tmax)

Time to maximum concentration for ceralasertib and olaparib are reported.

Time frame:
Cycle 1 (each cycle was 28 days in length) Day 1 (post-dose)
Reported as:
Median · Hour
Time to Maximum Concentration (Tmax)
HourCeralasertib (AZD6738)Olaparib
Time to Maximum Concentration (Tmax)1.250 (1.00 to 6.08)1.800 (1.00 to 6.08)
SecondaryMaximum Concentration (Cmax)

Maximum concentration for ceralasertib and olaparib are reported.

Time frame:
Cycle 1 (each cycle was 28 days in length) Day 1 (post-dose)
Reported as:
Geometric mean · µg/mL
Maximum Concentration (Cmax)
µg/mLCeralasertib (AZD6738)Olaparib
Maximum Concentration (Cmax)4.215 ± 27.71296.558 ± 39.9411
SecondaryPartial Area Under the Concentration-time Curve (AUC0-6)

Partial area under the concentration-time curve for ceralasertib and olaparib are reported.

Time frame:
Cycle 1 (each cycle was 28 days in length) Day 1 (post-dose) and Cycle 1 Day 7 (pre-dose and post-dose)
Reported as:
Geometric mean · h*µg/mL
Partial Area Under the Concentration-time Curve (AUC0-6)
h*µg/mLCeralasertib (AZD6738)Olaparib
Cycle 1, Day 118.346 ± 34.695226.356 ± 42.2963
Cycle 1, Day 723.666 ± 23.920242.016 ± 33.7599
SecondaryArea Under the Concentration-time Curve From Time Zero to the Last Measurable Concentration (AUC0-t)

Area under the concentration-time curve from time zero to the last measurable concentration for Ceralasertib and Olaparib are reported.

Time frame:
Cycle 1 (each cycle was 28 days in length) Day 1 (post-dose) and Cycle 1 Day 7 (pre-dose and post-dose)
Reported as:
Geometric mean · h*µg/mL
Area Under the Concentration-time Curve From Time Zero to the Last Measurable Concentration (AUC0-t)
h*µg/mLCeralasertib (AZD6738)Olaparib
Cycle 1, Day 118.575 ± 34.507426.973 ± 41.4461
Cycle 1, Day 724.061 ± 23.092362.535 ± 42.4552
SecondaryTime to Maximum Concentration at Steady State (Tmax,ss)

Time to maximum concentration at steady state for Ceralasertib and Olaparib are reported.

Time frame:
Cycle 1 (each cycle was 28 days in length) Day 7 (pre-dose and post-dose)
Reported as:
Median · Hour
Time to Maximum Concentration at Steady State (Tmax,ss)
HourCeralasertib (AZD6738)Olaparib
Time to Maximum Concentration at Steady State (Tmax,ss)1.875 (0.63 to 6.08)2.708 (0.63 to 4.50)
SecondaryMaximum Concentration at Steady State (Cmax,ss)

Maximum concentration at steady state for Ceralasertib and Olaparib are reported.

Time frame:
Cycle 1 (each cycle was 28 days in length) Day 7 (pre-dose and post-dose)
Reported as:
Geometric mean · µg/mL
Maximum Concentration at Steady State (Cmax,ss)
µg/mLCeralasertib (AZD6738)Olaparib
Maximum Concentration at Steady State (Cmax,ss)5.176 ± 23.40589.189 ± 30.4888
SecondaryMinimum Concentration at Steady State (Cmin,ss)

Minimum concentration at steady state for Ceralasertib and Olaparib are reported.

Time frame:
Cycle 1 (each cycle was 28 days in length) Day 7 (pre-dose and post-dose)
Reported as:
Geometric mean · µg/mL
Minimum Concentration at Steady State (Cmin,ss)
µg/mLCeralasertib (AZD6738)Olaparib
Minimum Concentration at Steady State (Cmin,ss)1.119 ± 55.90702.376 ± 61.8191
SecondaryArea Under the Concentration-time Curve at Steady State (AUCss)

Area under the concentration-time curve at steady state at steady state for Ceralasertib and Olaparib are reported.

Time frame:
Cycle 1 (each cycle was 28 days in length) Day 7 (pre-dose and post-dose)
Reported as:
Geometric mean · h*µg/mL
Area Under the Concentration-time Curve at Steady State (AUCss)
h*µg/mLCeralasertib (AZD6738)Olaparib
Area Under the Concentration-time Curve at Steady State (AUCss)NA ± NA67.929 ± 37.4297
SecondaryApparent Clearance of Drug at Steady State at Steady State (CLss/F)

Area under the concentration-time curve at steady state at steady state for Ceralasertib and Olaparib are reported.

Time frame:
Cycle 1 (each cycle was 28 days in length) Day 7 (pre-dose and post-dose)
Reported as:
Geometric mean · Litre/hour
Apparent Clearance of Drug at Steady State at Steady State (CLss/F)
Litre/hourCeralasertib (AZD6738)Olaparib
Apparent Clearance of Drug at Steady State at Steady State (CLss/F)NA ± NA4.416 ± 42.3171
SecondarySerum Concentrations of Durvalumab and Tremelimumab

Serum concentrations of Durvalumab and Tremelimumab are reported.

Time frame:
Durvalumab: Cycle 1 (each cycle was 4 weeks) Day 1(post-dose); Cycle 2 Day 1(pre-dose); Cycle 5 Day 1 (pre-dose); Tremelimumab: Cycle 1 (each cycle was 4 weeks) Day 1 (post-dose); Cycle 2 Day 1 (pre-dose); Cycle 5 Day 1 (No dose); Cycle 7 Day 1 (No dose)
Reported as:
Geometric mean · μg/mL
Serum Concentrations of Durvalumab and Tremelimumab
μg/mLArm A: Durvalumab + Tremelimumab (Original Cohort)
Durvalumab: Cycle 1 Day 1 (Post-dose)391.192 ± 23.5990
Durvalumab: Cycle 2 Day 1 (Pre-dose)55.590 ± 53.0745
Durvalumab: Cycle 5 Day 1 (Pre-dose)116.846 ± 51.0036
Tremelimumab: Cycle 1 Day 1 (Post-dose)18.299 ± 20.8181
Tremelimumab: Cycle 2 Day 1 (Pre-dose)2.650 ± 53.1007
Tremelimumab: Cycle 5 Day 1 (No dose)5.005 ± 38.3784
Tremelimumab: Cycle 7 Day 1 (No dose)0.784 ± 66.3469
SecondaryPlasma Concentrations of Adavosertib and Carboplatin

Plasma concentrations of Adavosertib and Carboplatin are reported.

Time frame:
Adavosertib: Cycle 1 (each cycle was 21 days) Day 3 (pre-dose and post-dose); Cycle 3 Day 3 (pre-dose and post-dose); Carboplatin: Cycle 1 (each cycle was 21 days) Day 1 (post-dose)
Reported as:
Geometric mean · nM
Plasma Concentrations of Adavosertib and Carboplatin
nMArm B: Adavosertib + Carboplatin
Adavosertib: Cycle 1 Day 3 (Pre-dose)551.489 ± 41.5823
Adavosertib: Cycle 1 Day 3 (Post-dose)728.342 ± 62.3968
Adavosertib: Cycle 3 Day 3 (Pre-dose)606.571 ± 46.7716
Adavosertib: Cycle 3 Day 3 (Post-dose)805.270 ± 68.0275
Carboplatin: Cycle 1 Day 1 (Post-dose)12834.615 ± 27.5493
SecondaryNumber of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)

An AE is the development of an undesirable medical condition or the deterioration of a pre-existing medical condition following or during exposure to a pharmaceutical product, whether or not considered causally related to the product. SAE is an AE that results in any untoward medical occurrence that results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability, or is a significant medical event.

Time frame:
Day 1 until disease progression, and follow-up visit (Up to 3.5 Years)
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
ParticipantsArm A: Durvalumab + Tremelimumab (Original Cohort)Arm A: Durvalumab + Tremelimumab (Expansion Cohort)Arm B: Adavosertib + CarboplatinArm C: Ceralasertib (AZD6738) + Olaparib
Any AE1617818
Any AE causally related to any study treatment109816
Any AE with outcome = death1011
Any SAE6847
Any AE leading to discontinuation of any study treatment2411

Adverse events

Collected over Day 1 until disease progression, and follow-up visit (Up to 3.5 Years). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Arm A: Durvalumab + Tremelimumab (Original Cohort)19/21 (90.5%)6/21 (28.6%)14/21 (66.7%)
Arm A: Durvalumab + Tremelimumab (Expansion Cohort)16/20 (80%)8/20 (40%)16/20 (80%)
Arm B: Adavosertib + Carboplatin10/10 (100%)4/10 (40%)8/10 (80%)
Arm C: Ceralasertib (AZD6738) + Olaparib15/21 (71.4%)7/21 (33.3%)13/21 (61.9%)
Most frequent serious events
Showing 10 of 23
Most frequent serious events
EventArm A: Durvalumab + Tremelimumab (Original Cohort)Arm A: Durvalumab + Tremelimumab (Expansion Cohort)Arm B: Adavosertib + CarboplatinArm C: Ceralasertib (AZD6738) + Olaparib
AnaemiaBlood and lymphatic system disorders0/211/200/104/21
DiarrhoeaGastrointestinal disorders2/211/201/100/21
Toxicity to various agentsInjury, poisoning and procedural complications1/210/201/100/21
HaematotoxicityBlood and lymphatic system disorders0/210/201/100/21
PancytopeniaBlood and lymphatic system disorders0/210/201/100/21
GastroenteritisInfections and infestations0/211/200/100/21
PneumoniaInfections and infestations0/211/200/101/21
Febrile neutropeniaBlood and lymphatic system disorders0/211/200/100/21
ThrombocytopeniaBlood and lymphatic system disorders0/211/200/101/21
HypokalaemiaMetabolism and nutrition disorders0/211/200/100/21
Most frequent other events
Showing 10 of 76
Most frequent other events
EventArm A: Durvalumab + Tremelimumab (Original Cohort)Arm A: Durvalumab + Tremelimumab (Expansion Cohort)Arm B: Adavosertib + CarboplatinArm C: Ceralasertib (AZD6738) + Olaparib
DiarrhoeaGastrointestinal disorders2/213/207/101/21
ThrombocytopeniaBlood and lymphatic system disorders0/211/207/101/21
NauseaGastrointestinal disorders0/213/206/103/21
AnaemiaBlood and lymphatic system disorders1/211/203/1011/21
FatigueGeneral disorders5/211/203/101/21
AstheniaGeneral disorders1/212/203/101/21
NeutropeniaBlood and lymphatic system disorders0/212/203/100/21
VomitingGastrointestinal disorders0/211/203/103/21
DyspnoeaRespiratory, thoracic and mediastinal disorders6/210/200/102/21
CoughRespiratory, thoracic and mediastinal disorders3/214/200/101/21

Baseline characteristics

The Full Analysis Set (FAS) included all treated participants.

Age, Customized
Age, Customized(Participants)Arm A: Durvalumab + Tremelimumab (Original Cohort)Arm A: Durvalumab + Tremelimumab (Expansion Cohort)Arm B: Adavosertib + CarboplatinArm C: Ceralasertib (AZD6738) + OlaparibTotal
< 5020125
≥ 50 to < 65131251242
≥ 65 to < 75663520
≥ 75 to < 8002125
≥ 8000000
Sex: Female, Male
Sex: Female, Male(Participants)Arm A: Durvalumab + Tremelimumab (Original Cohort)Arm A: Durvalumab + Tremelimumab (Expansion Cohort)Arm B: Adavosertib + CarboplatinArm C: Ceralasertib (AZD6738) + OlaparibTotal
Female642719
Male151681453
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Arm A: Durvalumab + Tremelimumab (Original Cohort)Arm A: Durvalumab + Tremelimumab (Expansion Cohort)Arm B: Adavosertib + CarboplatinArm C: Ceralasertib (AZD6738) + OlaparibTotal
Hispanic or Latino01001
Not Hispanic or Latino2119102171
Unknown or Not Reported00000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Arm A: Durvalumab + Tremelimumab (Original Cohort)Arm A: Durvalumab + Tremelimumab (Expansion Cohort)Arm B: Adavosertib + CarboplatinArm C: Ceralasertib (AZD6738) + OlaparibTotal
American Indian or Alaska Native00000
Asian00000
Native Hawaiian or Other Pacific Islander00000
Black or African American00000
White2120102172
More than one race00000
Unknown or Not Reported00000
08

Study locations

12 sites
  • Research Site
    Gauting, 82131, Germany
  • Research Site
    Kecskemét, 6000, Hungary
  • Research Site
    Miskolc, 3529, Hungary
  • Research Site
    Székesfehérvár, 8000, Hungary
  • Research Site
    Törökbálint, 2045, Hungary
  • Research Site
    Poznań, 60-569, Poland
  • Research Site
    Warszawa, 02-781, Poland
  • Research Site
    Sevilla, 41009, Spain
  • Research Site
    Valencia, 46009, Spain
  • Research Site
    Dnipro, 49102, Ukraine
  • Research Site
    Ivano-Frankivsk, 76018, Ukraine
  • Research Site
    Sumy, 40022, Ukraine
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2016 to primary completion in Jun 2020, 42 months.

Results were first posted in Sep 2021, 1 year 2 months after primary completion.

Of 54 industry-sponsored phase 2 interventional studies under Small Cell Lung Carcinoma, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 44. This study's 42 months is above that.

Counting every sponsor, half of 204 studies reached it within 46 months; a quarter within 29 and three quarters within 84.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 5, 2016
First posted
Oct 19, 2016
StartActual
Nov 28, 2016
Primary completionActual
Jun 22, 2020
CompletionActual
Nov 27, 2023
Results first posted
Sep 9, 2021
Last update
Jun 7, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 7, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02937818
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Oct 19, 2016
Start date
Nov 28, 2016
Primary completion
Jun 22, 2020
Completion
Nov 27, 2023
Results posted
Sep 9, 2021
Last update
Jun 7, 2024

Study contacts

Haiyi Jiang, M.D.
study director · AstraZeneca

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Adavosertib · Carboplatin · Ceralasertib · Olaparib · Durvalumab · Tremelimumab

Start the discussion